Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents

A compound of the general Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• Z1 is:
• Q is:
• Z2 is:
• Ar1 and Ar2 are independently selected from aryl, thiophenyl and phenyl;
• Ar1 may be optionally substituted with from 1 to 3 J groups;
• Ar2 is substituted with from 1 to 3 JJ groups;
• J is independently selected from halogen, —CN, —CF3, (C1-C3)haloalkyl, (C1-C6) optionally substituted alkyl, (C2-C3)alkynyl, (C1-C3)haloalkyoxy, (C1-C3) optionally substituted alkoxy, —C(O)OR15 and —C(O)R15;
• JJ is independently selected from halogen, —CF3, —CH3, (C1-C3)haloalkyl, (C1-C6) optionally substituted alkyl, (C2-C6)alkynyl, —CN, (C1-C3)haloalkyoxy, —C(O)OR15, —C(O)NR17R18, and (C1-C3) optionally substituted alkoxy;
• R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from hydrogen, halogen, —CH3, (C1-C3)alkyl and (C1-C3) optionally substituted alkyl;
• R14 is independently selected from hydrogen, halogen, —CN, —CH3, (C1-C3)alkyl, (C1-C6) optionally substituted alkyl, —NR17R18 and —C(O)R15;
• and
• R15, R17 and R18 are independently selected from hydrogen, —CH3, (C1-C3)alkyl, and (C1-C6) optionally substituted alkyl.